Suppr超能文献

鼓室内注射所致并发症的评估

Assessment of complications due to intratympanic injections.

作者信息

Liu Yu-Chuan, Chi Fan-Hsiang, Yang Ting-Hua, Liu Tien-Chen

机构信息

Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan, China.

Department of Otolaryngology, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan, China.

出版信息

World J Otorhinolaryngol Head Neck Surg. 2016 Feb 3;2(1):13-16. doi: 10.1016/j.wjorl.2015.11.001. eCollection 2016 Mar.

Abstract

OBJECTIVE

The purpose of the study is to report and to analyze the complications following intratympanic injections (ITI) of steroids. The occurrence rate of complications at different ITI sites, four quadrants of eardrum, was also compared.

METHODS

A retrospective clinical review in a medical center. Each patient received ITI twice in a week for 2-3 consecutive weeks as a salvage therapy for sudden sensorineural hearing loss. Post-injection complications, especially transient dizziness and vertigo, were recorded. Patients with acute or chronic vertigo episodes in 1 month were excluded.

RESULTS

A total of 59 patients with sudden sensorineural hearing loss and a total of 278 times of ITI were performed in 1 year. The post-injection complications included pain, tongue numbness, transient dizziness, vertigo, tinnitus, and a small persistent perforation. There was no significant difference in the occurrence of these complications between the injections sites on the 4 quadrants of the tympanic membrane. However, there was statistical significance in the post-injection vertiginous episode after IT injections to posterior-inferior quadrant (Q3) and posterior-superior quadrant (Q4) compared to anterior-superior quadrant (Q1) and anterior-inferior quadrant (Q2) ( = 0.0113).

CONCLUSION

IT injection is recommended to be applied to the Q2 since the Q1 and Q4 injections are more likely to induce the adverse effect of tongue numbness, while the Q3 and Q4 areas are more likely to induce post-injection vertigo.

摘要

目的

本研究旨在报告并分析鼓室内注射(ITI)类固醇后的并发症。同时比较在鼓膜四个象限不同ITI注射部位并发症的发生率。

方法

在一家医疗中心进行回顾性临床研究。每位患者每周接受两次ITI,连续进行2至3周,作为突发性感音神经性听力损失的挽救治疗。记录注射后的并发症,尤其是短暂性头晕和眩晕。排除在1个月内有急性或慢性眩晕发作的患者。

结果

1年内共对59例突发性感音神经性听力损失患者进行了278次ITI。注射后的并发症包括疼痛、舌麻木、短暂性头晕、眩晕、耳鸣和小的持续性穿孔。鼓膜四个象限注射部位之间这些并发症的发生率无显著差异。然而,与鼓膜前上象限(Q1)和前下象限(Q2)相比,向鼓膜后下象限(Q3)和后上象限(Q4)注射IT后,注射后眩晕发作有统计学意义(P = 0.0113)。

结论

建议将IT注射应用于Q2,因为Q1和Q4注射更易引发舌麻木的不良反应,而Q3和Q4区域更易引发注射后眩晕。

相似文献

1
Assessment of complications due to intratympanic injections.
World J Otorhinolaryngol Head Neck Surg. 2016 Feb 3;2(1):13-16. doi: 10.1016/j.wjorl.2015.11.001. eCollection 2016 Mar.
2
Complications and prognosis associated with intra-tympanic steroid injection to treat sudden sensorineural hearing impairment.
Am J Otolaryngol. 2022 Jan-Feb;43(1):103221. doi: 10.1016/j.amjoto.2021.103221. Epub 2021 Sep 10.
3
Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
Laryngoscope. 2007 Jan;117(1):3-15. doi: 10.1097/01.mlg.0000245058.11866.15.
4
[Intratympanic dexamethasone vesus post-auricular subperiosteal injection of methylprednisolone treatment for sudden hearing loss].
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Aug 20;31(16):1265-1268. doi: 10.13201/j.issn.1001-1781.2017.16.011.
5
Rate of tympanic membrane perforation after intratympanic steroid injection.
Am J Otolaryngol. 2017 Jan-Feb;38(1):21-25. doi: 10.1016/j.amjoto.2016.09.004. Epub 2016 Sep 28.
7
Clinical Practice Guideline: Sudden Hearing Loss (Update).
Otolaryngol Head Neck Surg. 2019 Aug;161(1_suppl):S1-S45. doi: 10.1177/0194599819859885.
8
Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary.
Otolaryngol Head Neck Surg. 2019 Aug;161(2):195-210. doi: 10.1177/0194599819859883.
9
Intratympanic steroid injection as a salvage treatment for sudden sensorineural hearing loss.
J Laryngol Otol. 2014 Dec;128(12):1044-9. doi: 10.1017/S0022215114002710. Epub 2014 Nov 17.
10
Intratympanic steroid injection for treatment of idiopathic sudden hearing loss.
Otolaryngol Head Neck Surg. 2005 Aug;133(2):251-9. doi: 10.1016/j.otohns.2005.05.015.

引用本文的文献

2
Primary versus salvage intratympanic steroid treatment for idiopathic sudden sensorineural hearing loss.
Laryngoscope Investig Otolaryngol. 2023 Jun 20;8(4):1029-1035. doi: 10.1002/lio2.1088. eCollection 2023 Aug.
4
Is repetitive systemic corticosteroid therapy effective for idiopathic sudden sensorineural hearing loss? a retrospective study.
Front Neurol. 2023 Apr 28;14:1167128. doi: 10.3389/fneur.2023.1167128. eCollection 2023.
5
Quality of life after intratympanic steroid injection for Ménière's disease.
Laryngoscope Investig Otolaryngol. 2022 May 17;7(3):825-831. doi: 10.1002/lio2.798. eCollection 2022 Jun.
6
Effects of Insulin-Like Growth Factor (IGF-1) in Patients with Sensorineural Hearing Loss.
J Int Adv Otol. 2021 May;17(3):207-214. doi: 10.5152/iao.2021.8549.
8
Autoimmune inner ear disease: A systematic review of management.
Laryngoscope Investig Otolaryngol. 2020 Nov 28;5(6):1217-1226. doi: 10.1002/lio2.508. eCollection 2020 Dec.

本文引用的文献

1
Clinical practice guideline: sudden hearing loss.
Otolaryngol Head Neck Surg. 2012 Mar;146(3 Suppl):S1-35. doi: 10.1177/0194599812436449.
2
Pain assessment of the intratympanic injections: a prospective comparative study.
Eur Arch Otorhinolaryngol. 2012 Dec;269(12):2467-73. doi: 10.1007/s00405-011-1897-z. Epub 2011 Dec 28.
3
Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
Laryngoscope. 2007 Jan;117(1):3-15. doi: 10.1097/01.mlg.0000245058.11866.15.
4
Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application.
Laryngoscope. 1999 Jul;109(7 Pt 2):1-17. doi: 10.1097/00005537-199907001-00001.
5
Treatment of vestibular disorders.
Acta Otolaryngol Suppl. 1991;481:617-23. doi: 10.3109/00016489109131486.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验